INmune Bio, Inc. (INMB)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about INmune Bio, Inc. (INMB)
Company Performance

Current Price

as of Oct 16, 2024

$5.21

P/E Ratio

N/A

Market Cap

$115.52M

Description

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Metrics

Overview

  • HQBoca Raton, FL
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerINMB
  • Price$5.21+7.87%

Trading Information

  • Market Cap$115.52M
  • Float71.10%
  • Average Daily Volume (1m)248,654
  • Average Daily Volume (3m)225,348
  • EPS-$2.06

Company

  • Revenue$0.08M
  • Rev Growth (1yr)-100.00%
  • Net Income-$9.75M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$9.87M
  • EV$144.65M
  • EV/Revenue1,701.80
  • P/EN/A
  • P/S1,183.43
  • P/B2.77
Documents
Factset
Factset Business Description
SEC Filings
8-K (2024-10-11)
8-K (2024-09-26)
8-K (2024-09-17)
8-K (2024-09-16)
8-K (2024-09-03)
8-K (2024-08-09)
8-K (2024-08-02)
8-K (2024-07-30)
8-K (2024-07-19)
8-K (2024-07-05)
8-K (2024-07-01)
8-K (2024-06-13)
8-K (2024-05-30)
8-K (2024-05-23)
8-K (2024-05-16)
8-K (2024-05-13)
8-K (2024-04-30)
8-K (2024-04-26)
8-K (2024-04-25)
8-K (2024-04-22)
8-K (2024-04-09)
8-K (2024-03-29)
8-K (2024-03-27)
8-K (2024-01-30)
8-K (2024-01-02)
8-K (2023-12-18)
8-K (2023-11-29)
8-K (2023-11-27)
8-K (2023-11-15)
8-K (2023-11-01)
8-K (2023-10-31)
8-K (2023-10-18)
8-K (2023-09-07)
8-K (2023-09-05)
8-K (2023-08-16)
8-K (2023-08-08)
8-K (2023-08-02)
8-K (2023-08-01)
8-K (2023-07-27)
8-K (2023-07-12)
8-K (2023-06-01)
8-K (2023-05-12)
8-K (2023-05-08)
8-K (2023-05-04)
8-K (2023-04-24)
8-K (2023-04-20)
8-K (2023-04-11)
8-K (2023-04-03)
8-K (2023-03-15)
8-K (2023-03-03)
8-K (2023-02-22)
8-K (2023-02-10)
8-K (2023-01-25)
10-Q (2024-08-01)
10-Q (2024-05-09)
10-Q (2023-11-01)
10-Q (2023-08-07)
10-Q (2023-05-03)
10-K (2024-03-28)
10-K (2023-03-02)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-11-01)
Earnings Report (2023-08-07)
Factset Street Account
Inmune Bio reports Q3 EPS ($0.48) vs FactSet ($0.39) [3 est, ($0.40)-(0.39)] ($7.07, 0.00) (2023-11-01T21:02:06Z)
INmune Bio receives EMA authorization in France and Spain for phase II trial of XPro in early Alzheimer's disease ($9.31, 0.00) (2023-11-27T13:07:09Z)
INmune Bio provides update regarding global Alzheimer's Phase II clinical trial and clinical hold issued by the FDA ($11.50, 0.00) (2023-12-19T12:24:46Z)
INmune Bio presents preclinical data at SITC 2023 ($6.95, 0.00) (2023-10-30T13:11:19Z)
INmune Bio presents new Biomarker and feasibility data from Phase 1B study supporting the use of XPro to treat Alzheimer's disease at CTAD Conference ($6.98, 0.00) (2023-10-17T12:03:04Z)
Inmune Bio demonstrates that INB03 enhances the uptake of Trastuzumab Deruxtecan in HER2+ breast cancer with MUC4 expression in poster presented at San Antonio Breast Cancer Symposium ($9.37, 0.00) (2023-11-29T13:05:55Z)
Inmune Bio announces expansion of phase ii clinical trial for Alzheimer's disease in Europe ($6.85, 0.00) (2023-11-15T14:02:51Z)